Stephen P Hack

Publication Activity (10 Years)

Years Active: 2020-2021
Publications (10 Years): 3

Top Topics

Chemotherapy Induced

Metastatic Colorectal Cancer

Top Venues

Future oncology (London, England)

Therapeutic advances in medical oncology

Expert opinion on investigational drugs

Genentech Inc

University of Birmingham (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Genentech Inc Jun 10 2011

United States

Senior Medical Director :: Product Development

Education History

University of Birmingham

United Kingdom

PHD

Publications

Stephen P Hack, Wendy Verret, Sohail Mulla, Bo Liu, Yulei Wang, Teresa Macarulla, Zhenggang Ren, Anthony B El-Khoueiry, Andrew X Zhu
IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Therapeutic advances in medical oncology 13 (2021)
Stephen P Hack, Andrew X Zhu
Atezolizumab: an investigational agent for the treatment of biliary tract cancer. Expert opinion on investigational drugs 30 (10) (2021)
Stephen P Hack, Jessica Spahn, Minshan Chen, Ann-Lii Cheng, Ahmed Kaseb, Masatoshi Kudo, Han Chu Lee, Adam Yopp, Pierce Chow, Shukui Qin
IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future oncology (London, England) 16 (15) (2020)